Notice of Completion: The 10 Year Analysis for Senate Bill 5983 is Complete

Office of Financial Management

Having trouble viewing this email? View it as a Web page.

Bookmark and Share

You are receiving this email as a subscriber to the Initiative 960 email list. RCW 43.135.031 (I-960) requires that notices be sent each time a bill that raises taxes or fees is: introduced in either house; scheduled for a public hearing; approved by any legislative committee; or passed by either house of the Legislature.

Please note: This email message was sent from a notification-only address. Please do not reply to this message.

SB 5983, titled AN ACT Relating to protecting consumers from untested and unregulated cannabinoid products by expanding agency regulatory authority over cannabinoids that may be impairing, modifying definitions in the uniform controlled substances act, prohibiting the sale of certain cannabinoid products except by licensed cannabis businesses, regulating the use of additives in cannabis products, requiring product testing and disclosures, prohibiting the manufacture and sale of artificial cannabinoids, requirin, has been introduced in the Senate. The Office of Financial Management has identified this bill as requiring a ten-year projection of increased cost to the taxpayers or affected fee payers.

Ten-year projection:

Liquor and Cannabis Board:

Section 13 creates a new $25 “license issuance and renewal surcharge” on vapor product retailers (RCW 70.345.030), cigarette retailers (RCW 82.24), and other tobacco product (OTP) retailers (RCW 82.26).  The surcharge does not apply to businesses classified as "supermarkets and other grocery stores" and "convenience stores" as described in the North American industry classification system. The surcharge is only assessed once per licensee, regardless of how many license types they hold and expires July 1, 2024.


Revenue impact is indeterminate as it is unknown how many vapor, cigarette, or OTP licensees fall under the exemption listed in Section 13(4).


Department of Revenue:

The revenue impact of this bill is indeterminate, as it is unknown what share of medical marijuana sales are products containing artificial or synthetically-derived cannabinoids.


Ten-year projection prepared in consultation with the following agencies:

Department of Revenue
Liquor and Cannabis Board

Bill sponsors and contact information:

Senator Karen Keiser, Prime Sponsor
(360) 786-7664

Senator Mark Schoesler
(360) 786-7620

Senator Steve Conway
(360) 786-7656

Senator Rebecca Saldaña
(360) 786-7688

Legislative Bill Information Website:

Initiative 960 Website: